воскресенье, 27 ноября 2016 г.

Is Eli Lilly A Buy After Their Recent Clinical Failure?

Is Eli Lilly A Buy After Their Recent Clinical Failure?


The research-based drug industry is rife with numerous failures. The process of bringing forth novel compounds is particularly perilous as adverse events may crop up scuttling the commercial viability of the product deep into phase three testing.



from Biotech News